Finch Therapeutics Group, Inc. (FNCHQ)
D
Pipeline Grade
Financial Position (from SEC Filings)
$18.4M
Cash & Equivalents
$9.1M
Quarterly Burn Rate
6 mo
Est. Cash Runway
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-21 | Phase3 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05129020 | Neurostimulation to Improve NOWS Outcomes | OTHER | Active Not Recruiting | 52 |
| NCT06112418 | A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | OTHER | Recruiting | 7,500 |
| NCT07281261 | tAN for Substance Use Disorder | OTHER | Recruiting | 20 |
| NCT07326722 | Delivering tAN to Reduce HMB: The LUNA Study | OTHER | Recruiting | 80 |
| NCT06647017 | Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures | OTHER | Recruiting | 40 |
| NCT06858878 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or A... | PHASE3 | Active Not Recruiting | 1,105 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.